Use of SSRIs during pregnancy and possible consequences for the development of the child;SSRI-gebruik in de zwangerschap en de mogelijke gevolgen voor de ontwikkeling van het kind

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 52, 2007, Pages 2873-2874

  Van Der Veere, C N ^a,b   Bos, A F ^a  

^a Wilhelmina Ziekenhuis   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

BEHAVIOR DISORDER; CHILD DEVELOPMENT; COGNITION; COGNITIVE DEFECT; CONVULSION; DIGESTIVE SYSTEM FUNCTION DISORDER; FEEDING DISORDER; HUMAN; IRRITABILITY; MAJOR DEPRESSION; MORBIDITY; NONHUMAN; NOTE; PERINATAL DRUG EXPOSURE; PREGNANCY; RESPIRATORY DISTRESS; RISK FACTOR; SIDE EFFECT;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; FEMALE; FETAL DEVELOPMENT; FETUS; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SEROTONIN UPTAKE INHIBITORS;

EID: 37649001050     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (11)

1. Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev. 2006;29:445-55.
2. Ververs T, Kaasenbrood H, Visser G, Schobben F, Jong-van den Berg L de, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol. 2006;62:863-70.
3. Gentile S. SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs. 2005;19:623-33.
4. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356:2675-83.
5. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006; 63:898-906.
6. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005; 106:1289-96.
7. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336:258-62.
8. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159:1889-95.
9. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RC, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology. 2006;31:47-57.
10. Xu Y, Sari Y, Zhou FC. Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Brain Res Dev Brain Res. 2004;150:151-61.
11. Watson RE, Desesso JM, Hurtt ME, Cappon GD. Postnatal growth and morphological development of the brain: a species comparison. Birth Defects Res B Dev Reprod Toxicol. 2006;77:471-84.